Keywords
Last Name

Benjamin Wolozin, MD, PhD

TitleProfessor
InstitutionBoston University School of Medicine
DepartmentPharmacology & Experimental Therapeutics
Address72 E. Concord St
Boston MA 02118
Phone(617) 414-2652
ORCID ORCID Icon0000-0003-2068-1475
Other Positions
TitleGraduate Faculty (Primary Mentor of Grad Students)
InstitutionBoston University School of Medicine, Graduate Medical Sciences

TitleProfessor
InstitutionBoston University School of Medicine
DepartmentNeurology

 Awards and Honors

Start-EndDescription
2013Alzheimer Association: Zenith Award
2013Boston University School of Medicine: Evans Center DOM Collaborator of the Year Award: Basic Sciences
2000Loyola University Medical Center: Graduate School Faculty of the Year
2000Loyola University Dept. of Pharmacology: Faculty of the Year
1988Society for Neuroscience: Donald B. Lindsley Prize
1993Society for Biological Psychiatry: A. E. Bennett Award
 Research Expertise & Professional Interests
Dr. Wolozin’s research examines the pathophysiology of neurodegenerative diseases, including Alzheimer’s disease, Amyotrophic Lateral Sclerosis and Parkinson’s disease. His laboratory is currently focused on the role of RNA binding proteins and translational regulation in disease processes.

Parkinson’s disease: The research on Parkinson Disease focuses on genetic factors implicated in Parkinson’s disease, including LRRK2, a-synuclein, parkin, PINK1 and DJ-1. Research in our laboratory suggests that genetic mutations linked to Parkinson’s disease act by converging on a biological system that integrates the stress response, regulating autophagy, protein translation and mitochondrial function. Using genetically modified cells (e.g., primary neuronal cultures or cell lines) and genetically modified animals (C. elegans and mice), we have demonstrated that a-synuclein and LRRK2 enhance the sensitivity of dopaminergic neurons to mitochondrial dysfunction. Our work points to particular biochemical pathways mediating the actions of LRRK2. We have recently demonstrated that LRRK2 binds to MKK6, a kinase that lies upstream of p38 and regulates the stress response. LRRK2 regulates membrane localization of its binding proteins, including MKKs, JIPs, rac1 (a small GTPase) and other important proteins mediating the stress response. This work has direct relevance to therapy because it points to chemicals that might protect dopaminergic neurons and modify the course of Parkinson’s disease. For instance, we are investigating the action of SirT1 agonists (such resveratrol, the compound found in red wine or SRT1720, produced by Sirtris Pharmaceuticals), which stimulate synthesis of anti-oxidant enzymes and appear to offer protection in animal models of Parkinson’s disease. We are also investigating the action of brain penetrant analogues of rapamycin, which stimulate the neuron to remove protein aggregates, and offer neuroprotection through mechanisms complementary to SirT1.

Amyotrophic Lateral Sclerosis (ALS): Our current work focuses on a protein, TDP-43, that was recently shown to be the predominant protein that accumulates during the course of the disease. We have shown that TDP-43 is a stress granule protein, and that TDP-43 pathology co-localizes with other stress granule markers in spinal cords of subjects with ALS, as well as those with Frontotemporal Dementia. We are currently examining how TDP-43 and disease-linked mutations in TDP-43 modify synaptic function in neuronal arbors. We are using protein binding assays (immunoprecipitation, mass spectrometry) and imaging assay (fixed cells and live cell imaging) to determine the effects of TDP-43 and its mutations. We use cell lines, primary cultures of hippocampal neurons and human brain samples for our studies.

We also have an active drug discover program related to TDP-43. This program utilizes cells that inducibly over-express TDP-43, as well as lines of C. elegans expressing TDP-43 and studies in primary cultures of hippocampal neurons. We examine the compounds using imaging (in collaboration with Marcie Glicksman at LDDN) and biochemistry.

Alzheimer disease (AD): We have recently extended our work on stress granules to Alzheimer’s disease. As with ALS, we have shown that tau pathology (neurofibrillary tangles) in the AD brain co-localizes with stress granule markers. The amount of stress granule pathology in the AD brain is very striking. Proteins such as TIA-1, G3BP and TTP, strongly accumulate. Interestingly, though, the pattern of accumulation differs based on the stress granule protein. The pathology appears to correlate with binding to tau protein. TIA-1 and TTP both bind to tau, while G3BP does not bind tau. Stress granules might also directly modulate tau pathology, because co-transfecting TIA-1 with tau induces formation of phosphorylated tau inclusions. The work on AD and stress granules uses biochemical/immunochemical studies focusing on proteins implicated in AD (e.g., antibodies to tau) and on stress granule markers. The work also uses extensive imaging assays (fixed cells, live cell imaging, confocal microscopy). We use studies of hippocampal neurons grown culture, transgenic mice expressing P301L tau and human tissues.

 Self-Described Keywords
  • Alzheimer's disease
  • Amyotrophic lateral sclerosis
  • biochemistry
  • C. elegans
  • cell culture
  • confocal microscopy
  • gene knockdown
  • gene over-expression
  • hippocampal neurons (in culture)
  • immumohistochemistry
  • immunochemistry
  • immunocytochemistry
  • immunoprecipitation
  • induced pluripotent stem cells
  • live cell imaging
  • mouse models
  • movement disorders
  • Parkinson's disease
  • RNAi
  • transfection
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Dusonchet J, Li H, Guillily M, Liu M, Stafa K, Derada Troletti C, Boon JY, Saha S, Glauser L, Mamais A, Citro A, Youmans KL, Liu-Yesucevitz L, Schneider BL, Aebischer P, Yue Z, Bandopadhyay R, Glicksman MA, Moore DJ, Collins JJ, Wolozin B. A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity. Hum Mol Genet. 2014 May 2.
    View in: PubMed
  2. Liu-Yesucevitz L, Lin AY, Ebata A, Boon JY, Reid W, Xu YF, Kobrin K, Murphy GJ, Petrucelli L, Wolozin B. ALS-Linked Mutations Enlarge TDP-43-Enriched Neuronal RNA Granules in the Dendritic Arbor. J Neurosci. 2014 Mar 19; 34(12):4167-74.
    View in: PubMed
  3. Wolozin B. Physiological protein aggregation run amuck: stress granules and the genesis of neurodegenerative disease. Discov Med. 2014 Jan; 17(91):47-52.
    View in: PubMed
  4. Wolozin B. Neurodegeneration: Twists, Turns and Tangles. In “Discoveries in Modern Science: Exploration, Invention, Technology” (McMillan Reference, Cengage Learning, Farmington Hills, MI). 2014.
  5. Leung A, Nah SK, Reid W, Ebata A, Koch CM, Monti S, Genereux JC, Wiseman RL, Wolozin B, Connors LH, Berk JL, Seldin DC, Mostoslavsky G, Kotton DN, Murphy GJ. Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis. Stem Cell Reports. 2013; 1(5):451-63.
    View in: PubMed
  6. Saha S, Liu-Yesucevitz L, Wolozin B. Regulation of Autophagy by LRRK2 in Caenorhabditis elegans. Neurodegener Dis. 2014; 13(2-3):110-3.
    View in: PubMed
  7. Boyd JD, Lee-Armandt JP, Feiler MS, Zaarur N, Liu M, Kraemer B, Concannon JB, Ebata A, Wolozin B, Glicksman MA. A High-Content Screen Identifies Novel Compounds That Inhibit Stress-Induced TDP-43 Cellular Aggregation and Associated Cytotoxicity. J Biomol Screen. 2014 Jan; 19(1):44-56.
    View in: PubMed
  8. Vanderweyde T, Youmans K, Liu-Yesucevitz L, Wolozin B. Role of stress granules and RNA-binding proteins in neurodegeneration: a mini-review. Gerontology. 2013; 59(6):524-33.
    View in: PubMed
  9. Rodriguez-Ortiz CJ, Hoshino H, Cheng D, Liu-Yescevitz L, Blurton-Jones M, Wolozin B, LaFerla FM, Kitazawa M. Neuronal-specific overexpression of a mutant valosin-containing protein associated with IBMPFD promotes aberrant ubiquitin and TDP-43 accumulation and cognitive dysfunction in transgenic mice. Am J Pathol. 2013 Aug; 183(2):504-15.
    View in: PubMed
  10. Ravid K, Wolozin B. The Scientist's Pledge. Acad Med. 2013 Jun; 88(6):743.
    View in: PubMed
  11. McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, Lee HS, Wojtowicz SM, Hall G, Baugh CM, Riley DO, Kubilus CA, Cormier KA, Jacobs MA, Martin BR, Abraham CR, Ikezu T, Reichard RR, Wolozin BL, Budson AE, Goldstein LE, Kowall NW, Cantu RC. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013 Jan; 136(Pt 1):43-64.
    View in: PubMed
  12. Wolozin B. Regulated protein aggregation: stress granules and neurodegeneration. Mol Neurodegener. 2012; 7:56.
    View in: PubMed
  13. Vanderweyde T, Yu H, Varnum M, Liu-Yesucevitz L, Citro A, Ikezu T, Duff K, Wolozin B. Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies. J Neurosci. 2012 Jun 13; 32(24):8270-83.
    View in: PubMed
  14. Youmans KL, Wolozin B. TDP-43: a new player on the AD field? Exp Neurol. 2012 Sep; 237(1):90-5.
    View in: PubMed
  15. Kim G, Meriin AB, Gabai VL, Christians E, Benjamin I, Wilson A, Wolozin B, Sherman MY. The heat shock transcription factor Hsf1 is downregulated in DNA damage-associated senescence, contributing to the maintenance of senescence phenotype. Aging Cell. 2012 Aug; 11(4):617-27.
    View in: PubMed
  16. Goldstein LE, Fisher AM, Tagge CA, Zhang XL, Velisek L, Sullivan JA, Upreti C, Kracht JM, Ericsson M, Wojnarowicz MW, Goletiani CJ, Maglakelidze GM, Casey N, Moncaster JA, Minaeva O, Moir RD, Nowinski CJ, Stern RA, Cantu RC, Geiling J, Blusztajn JK, Wolozin BL, Ikezu T, Stein TD, Budson AE, Kowall NW, Chargin D, Sharon A, Saman S, Hall GF, Moss WC, Cleveland RO, Tanzi RE, Stanton PK, McKee AC. Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med. 2012 May 16; 4(134):134ra60.
    View in: PubMed
  17. Di Domenico F, Sultana R, Ferree A, Smith K, Barone E, Perluigi M, Coccia R, Pierce W, Cai J, Mancuso C, Squillace R, Wiengele M, Dalle-Donne I, Wolozin B, Butterfield DA. Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease. Antioxid Redox Signal. 2012 Dec 1; 17(11):1490-506.
    View in: PubMed
  18. Devine MJ, Kaganovich A, Ryten M, Mamais A, Trabzuni D, Manzoni C, McGoldrick P, Chan D, Dillman A, Zerle J, Horan S, Taanman JW, Hardy J, Marti-Masso JF, Healy D, Schapira AH, Wolozin B, Bandopadhyay R, Cookson MR, van der Brug MP, Lewis PA. Correction: Pathogenic LRRK2 Mutations Do Not Alter Gene Expression in Cell Model Systems or Human Brain Tissue. PLoS One. 2012; 7(1).
    View in: PubMed
  19. Wolozin B. Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design. Alzheimers Res Ther. 2012; 4(1):3.
    View in: PubMed
  20. Liu Z, Zhu H, Fang GG, Walsh K, Mwamburi M, Wolozin B, Abdul-Hay SO, Ikezu T, Leissring MA, Qiu WQ. Characterization of insulin degrading enzyme and other amyloid-ß degrading proteases in human serum: a role in Alzheimer's disease? J Alzheimers Dis. 2012; 29(2):329-40.
    View in: PubMed
  21. Ferree A, Guillily M, Li H, Smith K, Takashima A, Squillace R, Weigele M, Collins JJ, Wolozin B. Regulation of physiologic actions of LRRK2: focus on autophagy. Neurodegener Dis. 2012; 10(1-4):238-41.
    View in: PubMed
  22. Liu-Yesucevitz L, Bassell GJ, Gitler AD, Hart AC, Klann E, Richter JD, Warren ST, Wolozin B. Local RNA translation at the synapse and in disease. J Neurosci. 2011 Nov 9; 31(45):16086-93.
    View in: PubMed
  23. Devine MJ, Kaganovich A, Ryten M, Mamais A, Trabzuni D, Manzoni C, McGoldrick P, Chan D, Dillman A, Zerle J, Horan S, Taanman JW, Hardy J, Marti-Masso JF, Healy D, Healey D, Schapira AH, Wolozin B, Bandopadhyay R, Cookson MR, van der Brug MP, Lewis PA. Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue. PLoS One. 2011; 6(7):e22489.
    View in: PubMed
  24. Chan D, Citro A, Cordy JM, Shen GC, Wolozin B. Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J Biol Chem. 2011 May 6; 286(18):16140-9.
    View in: PubMed
  25. Wolozin B, Gabel C, Ferree A, Guillily M, Ebata A. Watching worms whither: modeling neurodegeneration in C. elegans. Prog Mol Biol Transl Sci. 2011; 100:499-514.
    View in: PubMed
  26. Wolozin B. Live Report: Rally to Restore Sanity and/or Fear, a Plea for Reason. Skeptical Inquirer. 2011; 35(2).
  27. Wolozin B, Lee A, Li N C, Kazis L E. Pharmaco-epidemiological Studies Using the Veterans Affairs Health System Decision Support System Database. Efficient Decision Support Systems: Practice and Challenges – From Current to Future. 2011.
  28. Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderweyde T, Vanderwyde T, Citro A, Mehta T, Zaarur N, McKee A, Bowser R, Sherman M, Petrucelli L, Wolozin B. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One. 2010; 5(10):e13250.
    View in: PubMed
  29. Solomon A, Sippola R, Soininen H, Wolozin B, Tuomilehto J, Laatikainen T, Kivipelto M. Lipid-lowering treatment is related to decreased risk of dementia: a population-based study (FINRISK). Neurodegener Dis. 2010; 7(1-3):180-2.
    View in: PubMed
  30. Hsu CH, Chan D, Wolozin B. LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteins. Neurodegener Dis. 2010; 7(1-3):68-75.
    View in: PubMed
  31. Kumar A, Greggio E, Beilina A, Kaganovich A, Chan D, Taymans JM, Wolozin B, Cookson MR. The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One. 2010; 5(1):e8730.
    View in: PubMed
  32. Carballo-Carbajal I, Weber-Endress S, Rovelli G, Chan D, Wolozin B, Klein CL, Patenge N, Gasser T, Kahle PJ. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell Signal. 2010 May; 22(5):821-7.
    View in: PubMed
  33. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010; 340:b5465.
    View in: PubMed
  34. Hsu CH, Chan D, Greggio E, Saha S, Guillily MD, Ferree A, Raghavan K, Shen GC, Segal L, Ryu H, Cookson MR, Wolozin B. MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J Neurochem. 2010 Mar; 112(6):1593-604.
    View in: PubMed
  35. Vanderweyde T, Bednar MM, Forman SA, Wolozin B. Iatrogenic risk factors for Alzheimer's disease: surgery and anesthesia. J Alzheimers Dis. 2010; 22 Suppl 3:91-104.
    View in: PubMed
  36. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord. 2009; 28(1):75-80.
    View in: PubMed
  37. Saha S, Guillily MD, Ferree A, Lanceta J, Chan D, Ghosh J, Hsu CH, Segal L, Raghavan K, Matsumoto K, Hisamoto N, Kuwahara T, Iwatsubo T, Moore L, Goldstein L, Cookson M, Wolozin B. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci. 2009 Jul 22; 29(29):9210-8.
    View in: PubMed
  38. Tezapsidis N, Johnston JM, Smith MA, Ashford JW, Casadesus G, Robakis NK, Wolozin B, Perry G, Zhu X, Greco SJ, Sarkar S. Leptin: a novel therapeutic strategy for Alzheimer's disease. J Alzheimers Dis. 2009; 16(4):731-40.
    View in: PubMed
  39. Zerbinatti CV, Cordy JM, Chen CD, Guillily M, Suon S, Ray WJ, Seabrook GR, Abraham CR, Wolozin B. Oxysterol-binding protein-1 (OSBP1) modulates processing and trafficking of the amyloid precursor protein. Mol Neurodegener. 2008; 3:5.
    View in: PubMed
  40. Wolozin B, Saha S, Guillily M, Ferree A, Riley M. Investigating convergent actions of genes linked to familial Parkinson's disease. Neurodegener Dis. 2008; 5(3-4):182-5.
    View in: PubMed
  41. Frasier M, Frausto S, Lewicki D, Golbe L, Wolozin B. DJ-1 Expression Increases in Mice Over-Expressing A30P a-Synuclein. ALZHEIMER’S AND PARKINSON’S DISEASES: INSIGHTS,PROGRESS AND PERSPECTIVES (Eds., Hanin and Fisher, Springer, NY). 2008.
  42. Solomon A, Kåreholt I, Ngandu T, Wolozin B, Macdonald SW, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M. Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol Aging. 2009 Jun; 30(6):1006-9.
    View in: PubMed
  43. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007; 5:20.
    View in: PubMed
  44. Wolozin B. The Art of Persuasion in Politics, Skeptical Inquirer. 2007; 31(1).
  45. Wolozin B, Bednar MM. Interventions for heart disease and their effects on Alzheimer's disease. Neurol Res. 2006 Sep; 28(6):630-6.
    View in: PubMed
  46. Takashima A, Shimojo M, Wolozin B. The players on the gamma-secretase team. Nat Med. 2006 Jul; 12(7):766-7; discussion 767.
    View in: PubMed
  47. Bednar MM, Lee TA, Wolozin B, Weiss KB. Coronary artery bypass grafting is not a risk factor for dementia or Alzheimer disease. Neurology. 2006 Jun 13; 66(11):1785; author reply 1785.
    View in: PubMed
  48. Wolozin B. Interpreting Clinical Studies of Putative Therapeutics for Alzheimer’s disease. In, ed. Cuello, C., Pharmacological and Mechanisms in Alzheimer’s Therapeutics. 2006.
  49. Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A. Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl. 2006; 185:63-70.
    View in: PubMed
  50. Cordy, J.M. Wolozin, B. Cholesterol and Alzheimer’s disease. In eds Barrow C.J., Small D.H.. Abeta Peptide and Alzheimer's Disease: Celebrating a Century of Research. Springer-Verlag. London. 2006; 312.
  51. Wolozin H, Wolozin B. The Unconscious in Economic Decision-Making. Convergent Voices. Journal of Socio-Economics. 2006.
  52. Wolozin B. Cholesterol, Statins and Alzheimer’s disease: Past, Present and Future. In, ed. Sun, M. K., Research Progress in Alzheimer’s Disease and Dementia. 2006.
  53. Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, Hoener M, Rodrigues CM, Alfonso A, Steer C, Liu L, Przedborski S, Wolozin B. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem. 2005 Dec 30; 280(52):42655-68.
    View in: PubMed
  54. Lee TA, Wolozin B, Weiss KB, Bednar MM. Assessment of the emergence of Alzheimer's disease following coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty. J Alzheimers Dis. 2005 Aug; 7(4):319-24.
    View in: PubMed
  55. Frasier M, Walzer M, McCarthy L, Magnuson D, Lee JM, Haas C, Kahle P, Wolozin B. Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp Neurol. 2005 Apr; 192(2):274-87.
    View in: PubMed
  56. Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, Butterfield DA. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease. Neurobiol Dis. 2005 Apr; 18(3):492-8.
    View in: PubMed
  57. Snyder H, Mensah K, Hsu C, Hashimoto M, Surgucheva IG, Festoff B, Surguchov A, Masliah E, Matouschek A, Wolozin B. beta-Synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-synuclein. J Biol Chem. 2005 Mar 4; 280(9):7562-9.
    View in: PubMed
  58. Wolozin B. Cholesterol, statins and dementia. Curr Opin Lipidol. 2004 Dec; 15(6):667-72.
    View in: PubMed
  59. Wolozin B. Apolipoprotein E receptor LR11: intersections between neurodegeneration and cholesterol metabolism. Arch Neurol. 2004 Aug; 61(8):1178-80.
    View in: PubMed
  60. Frasier M, Wolozin B. Following the leader: fibrillization of alpha-synuclein and tau. Exp Neurol. 2004 Jun; 187(2):235-9.
    View in: PubMed
  61. Brown J, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, Yager D, Crowley J, Sambamurti K, Rahman MM, Reiss AB, Eckman CB, Wolozin B. Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem. 2004 Aug 13; 279(33):34674-81.
    View in: PubMed
  62. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B, Hardy J, Hutton M. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet. 2004 Apr 1; 13(7):703-14.
    View in: PubMed
  63. Ghanbari HA, Ghanbari K, Harris PL, Jones PK, Kubat Z, Castellani RJ, Wolozin BL, Smith MA, Perry G. Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients. Aging Cell. 2004 Feb; 3(1):41-4.
    View in: PubMed
  64. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron. 2004 Jan 8; 41(1):7-10.
    View in: PubMed
  65. Wolozin B, Brown J, Theisler C, Silberman S. The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease. CNS Drug Rev. 2004; 10(2):127-46.
    View in: PubMed
  66. Snyder H, Wolozin B. Pathological proteins in Parkinson's disease: focus on the proteasome. J Mol Neurosci. 2004; 24(3):425-42.
    View in: PubMed
  67. Choi P, Snyder H, Petrucelli L, Theisler C, Chong M, Zhang Y, Lim K, Chung KK, Kehoe K, D'Adamio L, Lee JM, Cochran E, Bowser R, Dawson TM, Wolozin B. SEPT5_v2 is a parkin-binding protein. Brain Res Mol Brain Res. 2003 Oct 7; 117(2):179-89.
    View in: PubMed
  68. Perry G, Castellani RJ, Smith MA, Harris PL, Kubat Z, Ghanbari K, Jones PK, Cordone G, Tabaton M, Wolozin B, Ghanbari H. Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol. 2003 Dec; 106(6):552-6.
    View in: PubMed
  69. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, Girones X, Henry TL, Matsubara E, Zambon D, Wolozin B, Sano M, Cruz-Sanchez FF, Thal LJ, Petanceska SS, Refolo LM. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 2003 Jul 22; 61(2):199-205.
    View in: PubMed
  70. Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B. Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J Biol Chem. 2003 Apr 4; 278(14):11753-9.
    View in: PubMed
  71. Wolozin B. Cyp46 (24S-cholesterol hydroxylase): a genetic risk factor for Alzheimer disease. Arch Neurol. 2003 Jan; 60(1):16-8.
    View in: PubMed
  72. Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J, Cookson MR. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron. 2002 Dec 19; 36(6):1007-19.
    View in: PubMed
  73. Egashira N, Iwasaki K, Ishibashi M, Hatip-Al-Khatib I, Wolozin B, Mishima K, Irie K, Fujiwara M. Hypoxia enhances beta-amyloid-induced apoptosis in rat cultured hippocampal neurons. Jpn J Pharmacol. 2002 Dec; 90(4):321-7.
    View in: PubMed
  74. Wolozin B. Cholesterol and Alzheimer's disease. Biochem Soc Trans. 2002 Aug; 30(4):525-9.
    View in: PubMed
  75. Golts N, Snyder H, Frasier M, Theisler C, Choi P, Wolozin B. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J Biol Chem. 2002 May 3; 277(18):16116-23.
    View in: PubMed
  76. Wolozin B, Golts N. Iron and Parkinson's disease. Neuroscientist. 2002 Feb; 8(1):22-32.
    View in: PubMed
  77. Ahn BH, Rhim H, Kim SY, Sung YM, Lee MY, Choi JY, Wolozin B, Chang JS, Lee YH, Kwon TK, Chung KC, Yoon SH, Hahn SJ, Kim MS, Jo YH, Min DS. alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. J Biol Chem. 2002 Apr 5; 277(14):12334-42.
    View in: PubMed
  78. Choi P, Golts N, Snyder H, Chong M, Petrucelli L, Hardy J, Sparkman D, Cochran E, Lee JM, Wolozin B. Co-association of parkin and alpha-synuclein. Neuroreport. 2001 Sep 17; 12(13):2839-43.
    View in: PubMed
  79. Palacino JJ, Murphy MP, Murayama O, Iwasaki K, Fujiwara M, Takashima A, Golde TE, Wolozin B. Presenilin 1 regulates beta-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion. J Biol Chem. 2001 Oct 19; 276(42):38563-9.
    View in: PubMed
  80. Wolozin B. A fluid connection: cholesterol and Abeta. Proc Natl Acad Sci U S A. 2001 May 8; 98(10):5371-3.
    View in: PubMed
  81. Wolozin B. Peering into proteolysis with presenilins. J Alzheimers Dis. 2001 Apr; 3(2):191-193.
    View in: PubMed
  82. Wolozin B, Siegel G. Response to Letter: Statin Therapy and the Prevention of Dementia. Archives Neurol. 2001; 58:1023.
  83. Wolozin B. Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design. Alzheimer's Research & Therapy. 2001; 4:3.
  84. Wolozin B. Peering into proteolylsis with presenilins. 2001; 3:191-193.
  85. Wolozin B, Siegel G. Response to Letter: Statin-Alzheimer Disease Association Not Yet Proven. Archives Neurol. 2001; 58:10.
  86. Wolozin B, Siegel G. Response to letter: Statins and Dementia. Archives Neurol. 2001; 58:1169.
  87. Wolozin B, Golts N, Choi P, Frasier M, Snyder H, Palacino, J. Looking beyond b-amyloid: a-Synuclein and Neurodegeneration. Research and Practice in Alzheimer’s disease. 2001; 4.
  88. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000 Oct; 57(10):1439-43.
    View in: PubMed
  89. Choi P, Ostrerova-Golts N, Sparkman D, Cochran E, Lee JM, Wolozin B. Parkin is metabolized by the ubiquitin/proteosome system. Neuroreport. 2000 Aug 21; 11(12):2635-8.
    View in: PubMed
  90. Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci. 2000 Aug 15; 20(16):6048-54.
    View in: PubMed
  91. Wolozin B, Behl C. Mechanisms of neurodegenerative disorders: Part 1: protein aggregates. Arch Neurol. 2000 Jun; 57(6):793-6.
    View in: PubMed
  92. Wolozin B, Behl C. Mechanisms of neurodegenerative disorders: Part 2: control of cell death. Arch Neurol. 2000 Jun; 57(6):801-4.
    View in: PubMed
  93. Palacino JJ, Berechid BE, Alexander P, Eckman C, Younkin S, Nye JS, Wolozin B. Regulation of amyloid precursor protein processing by presenilin 1 (PS1) and PS2 in PS1 knockout cells. J Biol Chem. 2000 Jan 7; 275(1):215-22.
    View in: PubMed
  94. Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, Lasser R, Motter R, Lehtimäki T, Seubert P. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry. 1999 Sep 15; 46(6):750-5.
    View in: PubMed
  95. Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, Wolozin B. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci. 1999 Jul 15; 19(14):5782-91.
    View in: PubMed
  96. Abrams MT, Kaufmann WE, Rousseau F, Oostra BA, Wolozin B, Taylor CV, Lishaa N, Morel ML, Hoogeveen A, Reiss AL. FMR1 gene expression in olfactory neuroblasts from two males with fragile X syndrome. Am J Med Genet. 1999 Jan 1; 82(1):25-30.
    View in: PubMed
  97. Wolozin B. Genes, Behaviour and Health. Alzheimer’s Disease. 1999; 123-144.
  98. Wolozin B, Maheshwari S, Jones C, Dukoff R, Wallace W, Racchi M, Nagula S, Shulman NR, Sunderland T, Bush A. Beta-amyloid augments platelet aggregation: reduced activity of familial angiopathy-associated mutants. Mol Psychiatry. 1998 Nov; 3(6):500-7.
    View in: PubMed
  99. Murayama M, Tanaka S, Palacino J, Murayama O, Honda T, Sun X, Yasutake K, Nihonmatsu N, Wolozin B, Takashima A. Direct association of presenilin-1 with beta-catenin. FEBS Lett. 1998 Aug 14; 433(1-2):73-7.
    View in: PubMed
  100. Takashima A, Murayama M, Murayama O, Kohno T, Honda T, Yasutake K, Nihonmatsu N, Mercken M, Yamaguchi H, Sugihara S, Wolozin B. Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc Natl Acad Sci U S A. 1998 Aug 4; 95(16):9637-41.
    View in: PubMed
  101. Wolozin B, Palacino J. Presenilins and their role in apoptosis. n eds. C. Haass, The Molecular Biology of Alzheimer’s Disease. Harwood Academic Publishers. Australia. 1998; 247-76.
  102. Wolozin B, Alexander P, Palacino J. Regulation of apoptosis by presenilin 1. Neurobiol Aging. 1998 Jan-Feb; 19(1 Suppl):S23-7.
    View in: PubMed
  103. Wallace WC, Akar CA, Lyons WE, Kole HK, Egan JM, Wolozin B. Amyloid precursor protein requires the insulin signaling pathway for neurotrophic activity. Brain Res Mol Brain Res. 1997 Dec 15; 52(2):213-27.
    View in: PubMed
  104. Goldstein BJ, Wolozin BL, Schwob JE. FGF2 suppresses neuronogenesis of a cell line derived from rat olfactory epithelium. J Neurobiol. 1997 Oct; 33(4):411-28.
    View in: PubMed
  105. Luo Y, Hawver DB, Iwasaki K, Sunderland T, Roth GS, Wolozin B. Physiological levels of beta-amyloid peptide stimulate protein kinase C in PC12 cells. Brain Res. 1997 Sep 26; 769(2):287-95.
    View in: PubMed
  106. Wolozin B. ICE and apoptosis. Mol Psychiatry. 1997 May; 2(3):184-7.
    View in: PubMed
  107. Vito P, Wolozin B, Ganjei JK, Iwasaki K, Lacanà E, D'Adamio L. Requirement of the familial Alzheimer's disease gene PS2 for apoptosis. Opposing effect of ALG-3. J Biol Chem. 1996 Dec 6; 271(49):31025-8.
    View in: PubMed
  108. Wolozin B, Iwasaki K, Vito P, Ganjei JK, Lacanà E, Sunderland T, Zhao B, Kusiak JW, Wasco W, D'Adamio L. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science. 1996 Dec 6; 274(5293):1710-3.
    View in: PubMed
  109. Wolozia B. Reductionist science and Alzheimer's disease: redoubling our effort in redox chemistry. Mol Psychiatry. 1996 Nov; 1(5):352-5.
    View in: PubMed
  110. Vawter MP, Basaric-Keys J, Li Y, Lester DS, Lebovics RS, Lesch KP, Kulaga H, Freed WJ, Sunderland T, Wolozin B. Human olfactory neuroepithelial cells: tyrosine phosphorylation and process extension are increased by the combination of IL-1beta, IL-6, NGF, and bFGF. Exp Neurol. 1996 Nov; 142(1):179-94.
    View in: PubMed
  111. Luo Y, Sunderland T, Roth GS, Wolozin B. Physiological levels of beta-amyloid peptide promote PC12 cell proliferation. Neurosci Lett. 1996 Oct 18; 217(2-3):125-8.
    View in: PubMed
  112. Luo Y, Sunderland T, Wolozin B. Physiologic levels of beta-amyloid activate phosphatidylinositol 3-kinase with the involvement of tyrosine phosphorylation. J Neurochem. 1996 Sep; 67(3):978-87.
    View in: PubMed
  113. Iwasaki K, Sunderland T, Kusiak JW, Wolozin B. Changes in gene transcription during a beta-mediated cell death. Mol Psychiatry. 1996 Mar; 1(1):65-71.
    View in: PubMed
  114. Wolozin BL, Basaric-Keys J, Canter R, Li Y, Vanderputten D, Sunderland T. Differential regulation of APP secretion by apolipoprotein E3 and E4. Ann N Y Acad Sci. 1996 Jan 17; 777:322-6.
    View in: PubMed
  115. Wolozin B, Luo Y, Wood K. Neuronal Loss and Aging in Cellular Aging and Cell Death. John Wiley & Sons, Inc. NY. 1996; 283-302.
  116. Wolozin B L, Basaric-Keys J, Canter R, VanderPutten D, Sunderland T. Differential regulation of APP by apolipoprotein E3 and E4. Ann. NY Acad. Sci. 1996; 777:322-326.
  117. Wolozin B, Hirashima N, Luo Y, Li YH, Alkon DL, Etcheberrigaray R, Sunderland T. Transforming growth factor beta induces a beta-responsive calcium fluxes in neurons. Neuroreport. 1995 Jul 10; 6(10):1429-33.
    View in: PubMed
  118. Luo YQ, Hirashima N, Li YH, Alkon DL, Sunderland T, Etcheberrigaray R, Wolozin B. Physiological levels of beta-amyloid increase tyrosine phosphorylation and cytosolic calcium. Brain Res. 1995 May 29; 681(1-2):65-74.
    View in: PubMed
  119. Lesch KP, Gross J, Franzek E, Wolozin BL, Riederer P, Murphy DL. Primary structure of the serotonin transporter in unipolar depression and bipolar disorder. Biol Psychiatry. 1995 Feb 15; 37(4):215-23.
    View in: PubMed
  120. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan Hua, Vitale J, Wadsworth S, Wolozin B, Zhao J. Development of neuropathology similar to Alzheimer's Disease in transgenic mice overexpressing the 717V-F b-amyloid precursor protein. Nature,. 1995; 373:523-528.
  121. Johnson GS, Basaric-Keys J, Ghanbari HA, Lebovics RS, Lesch KP, Merril CR, Sunderland T, Wolozin B. Protein alterations in olfactory neuroblasts from Alzheimer donors. Neurobiol Aging. 1994 Nov-Dec; 15(6):675-80.
    View in: PubMed
  122. Lesch KP, Gross J, Wolozin BL, Franzek E, Bengel D, Riederer P, Murphy DL. Direct sequencing of the reserpine-sensitive vesicular monamine transporter complementary DNA in unipolar depression and manic depressive illness. Psychiatr Genet. 1994; 4(3):153-60.
    View in: PubMed
  123. Lesch KP, Balling U, Gross J, Strauss K, Wolozin BL, Murphy DL, Riederer P. Organization of the human serotonin transporter gene. J Neural Transm Gen Sect. 1994; 95(2):157-62.
    View in: PubMed
  124. Wolozin B, Lesch P, Lebovics R, Sunderland T. A.E. Bennett Research Award 1993. Olfactory neuroblasts from Alzheimer donors: studies on APP processing and cell regulation. Biol Psychiatry. 1993 Dec 15; 34(12):824-38.
    View in: PubMed
  125. Lesch KP, Wolozin BL, Murphy DL, Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem. 1993 Jun; 60(6):2319-22.
    View in: PubMed
  126. Wolozin B L. The processing of amyloid precursor protein. Foundation Ipsen: Alzheimer Actualities. 1993; 7:6-8.
  127. Lesch KP, Wolozin BL, Estler HC, Murphy DL, Riederer P. Isolation of a cDNA encoding the human brain serotonin transporter. J Neural Transm Gen Sect. 1993; 91(1):67-72.
    View in: PubMed
  128. Lesch K P, Aulakh C S, Wolozin B L, Riederer P, Hill J L,Murphy D L. Norepinephrine, serotonin and vesicular monoamine transporter in depression and bipolar disorder. Expression during long-term antidepressant treatment. Neuropsychopharmacology. 1993; 9:34S-35S.
  129. Lesch KP, Aulakh CS, Wolozin BL, Tolliver TJ, Hill JL, Murphy DL. Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Brain Res Mol Brain Res. 1993 Jan; 17(1-2):31-5.
    View in: PubMed
  130. Lesch KP, Gross J, Wolozin BL, Murphy DL, Riederer P. Extensive sequence divergence between the human and rat brain vesicular monoamine transporter: possible molecular basis for species differences in the susceptibility to MPP+. J Neural Transm Gen Sect. 1993; 93(1):75-82.
    View in: PubMed
  131. Wolozin B, Zheng B, Loren D, Lesch KP, Lebovics RS, Lieberburg I, Sunderland T. Beta/A4 domain of APP: antigenic differences between cell lines. J Neurosci Res. 1992 Oct; 33(2):189-95.
    View in: PubMed
  132. Lesch KP, Hough CJ, Aulakh CS, Wolozin BL, Tolliver TJ, Hill JL, Akiyoshi J, Chuang DM, Murphy DL. Fluoxetine modulates G protein alpha s, alpha q, and alpha 12 subunit mRNA expression in rat brain. Eur J Pharmacol. 1992 Oct 1; 227(2):233-7.
    View in: PubMed
  133. Lesch KP, Aulakh CS, Wolozin BL, Hill JL, Murphy DL. 3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid decreases NMDA receptor mRNA. Eur J Pharmacol. 1992 Sep 1; 227(1):109-11.
    View in: PubMed
  134. Wolozin B, Bacic M, Merrill MJ, Lesch KP, Chen C, Lebovics RS, Sunderland T. Differential expression of carboxyl terminal derivatives of amyloid precursor protein among cell lines. J Neurosci Res. 1992 Sep; 33(1):163-9.
    View in: PubMed
  135. Lesch KP, Aulakh CS, Wolozin BL, Murphy DL. Serotonin (5-HT) receptor, 5-HT transporter and G protein-effector expression: implications for depression. Pharmacol Toxicol. 1992; 71 Suppl 1:49-60.
    View in: PubMed
  136. Wolozin B, Sunderland T, Zheng BB, Resau J, Dufy B, Barker J, Swerdlow R, Coon H. Continuous culture of neuronal cells from adult human olfactory epithelium. J Mol Neurosci. 1992; 3(3):137-46.
    View in: PubMed
  137. Lesch KP, Aulakh CS, Tolliver TJ, Hill JL, Wolozin BL, Murphy DL. Differential effects of long-term lithium and carbamazepine administration on Gs alpha and Gi alpha protein in rat brain. Eur J Pharmacol. 1991 Aug 14; 207(4):355-9.
    View in: PubMed
  138. Wolozin B L. Immunochemical approaches to the diagnosis of Alzheimer's Disease. In: Becker, R.E., and Giacobini, E. (Eds.) Alzheimer's Disease. Current Research in Early Diagnosis, Taylor and Francis. New York. 1990; 217-235.
  139. Wolozin B, Scicutella A, Davies P. Reexpression of a developmentally regulated antigen in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1988 Aug; 85(16):6202-6.
    View in: PubMed
  140. Hyman BT, Van Hoesen GW, Wolozin BL, Davies P, Kromer LJ, Damasio AR. Alz-50 antibody recognizes Alzheimer-related neuronal changes. Ann Neurol. 1988 Apr; 23(4):371-9.
    View in: PubMed
  141. Wolozin B, Davies P. Alzheimer-related neuronal protein A68: specificity and distribution. Ann Neurol. 1987 Oct; 22(4):521-6.
    View in: PubMed
  142. Davies P, Wolozin BL. Recent advances in the neurochemistry of Alzheimer's disease. J Clin Psychiatry. 1987 May; 48 Suppl:23-30.
    View in: PubMed
  143. Wolozin B L,Davies P. Recent advances in the neurochemistry of Alzheimer's Disease. J. Clin. Psychiatry. 1987; 48:23-30.
  144. Wolozin B L. A neuronal antigen in the brains of Alzheimer patients (Graduate Dissertation). 1987.
  145. Wolozin BL, Pruchnicki A, Dickson DW, Davies P. A neuronal antigen in the brains of Alzheimer patients. Science. 1986 May 2; 232(4750):648-50.
    View in: PubMed
  146. Wolozin BL, Nishimura S, Pasternak GW. The binding of kappa- and sigma-opiates in rat brain. J Neurosci. 1982 Jun; 2(6):708-13.
    View in: PubMed
  147. Wolozin BL, Myerowitz R, Pratt RF. Specific chemical modification of the readily nitrated tyrosine of the RTEM beta-lactamase and of bacillus cereus beta-lactamase I. The role of the tyrosine in beta-lactamase catalysis. Biochim Biophys Acta. 1982 Feb 18; 701(2):153-63.
    View in: PubMed
  148. Wolozin BL, Pasternak GW. Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc Natl Acad Sci U S A. 1981 Oct; 78(10):6181-5.
    View in: PubMed
  149. Wolozin B L. Towards an understanding of beta-lactamase catalysis. 1980.
Benjamin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department